Reclast (Zoledronic Acid) Side Effects, Withdrawal, and Discontinuation Syndrome

What Is Zoledronic Acid and How Is It Used?

Zoledronic acid is a nitrogen-containing bisphosphonate given as a single 5 mg intravenous infusion once per year for postmenopausal osteoporosis, osteoporosis in men, and glucocorticoid-induced bone loss. The FDA approved Reclast for postmenopausal osteoporosis in 2007 based on the HORIZON Key Fracture Trial (HORIZON-PFT). A separate 4 mg formulation (Zometa) is used at higher doses and more frequent intervals for skeletal complications of malignancy, but the adverse-event profile differs substantially from osteoporosis dosing.

Mechanism Relevant to Side Effects

Zoledronic acid binds avidly to hydroxyapatite in bone and inhibits farnesyl pyrophosphate synthase inside osteoclasts, triggering osteoclast apoptosis. This mechanism explains both the drug's efficacy and its side effects. Nitrogen-containing bisphosphonates can stimulate gamma-delta T cells to release cytokines, which drives the acute post-infusion fever-and-flu syndrome. The same prolonged skeletal retention, measured in years to decades, underpins the delayed adverse effects seen after stopping therapy [1].

FDA-Approved Indications

The prescribing label lists postmenopausal osteoporosis (treatment and prevention), osteoporosis in men, glucocorticoid-induced osteoporosis, and Paget disease of bone [2]. Each indication carries a distinct dosing interval and a distinct risk-benefit calculation.

Acute Post-Infusion Reaction (the "Flu-Like" Syndrome)

The most common adverse event after a first zoledronic acid infusion is an acute-phase reaction consisting of fever, myalgia, arthralgia, headache, and fatigue. In HORIZON-PFT (N=7,765), this reaction occurred in approximately 32% of patients receiving zoledronic acid versus 6% receiving placebo after the first infusion [3]. Symptoms typically begin within 24 to 48 hours and resolve within three days without specific treatment.

Who Is at Greatest Risk

First-time recipients carry the highest risk. After the second annual infusion, the reaction rate drops to roughly 6 to 7%, and it declines further with each subsequent dose. Patients who are vitamin D deficient at baseline, have lower pre-treatment bone turnover markers, or are younger than 65 appear to have higher reaction rates in observational data.

Management

Acetaminophen 500 to 1,000 mg or ibuprofen 400 mg taken before and for 24 to 72 hours after infusion reduces symptom severity. A 2011 randomized controlled trial (N=120) published in the Journal of Bone and Mineral Research confirmed that pre-treatment with acetaminophen significantly reduced fever rates compared to placebo [4]. Adequate pre-infusion hydration with at least 500 mL of fluid also lowers the incidence of post-infusion symptoms and reduces the risk of renal adverse events.

Hypocalcemia

Zoledronic acid suppresses osteoclast activity sharply after infusion, reducing calcium release from bone. Patients with vitamin D deficiency, hypoparathyroidism, recent thyroid or parathyroid surgery, or significant renal impairment face the highest hypocalcemia risk. The FDA prescribing label states that hypocalcemia has been reported and can be severe; it must be corrected before initiating therapy [2].

Prevention Protocol

The American Society for Bone and Mineral Research (ASBMR) task force recommends ensuring serum 25-hydroxyvitamin D is above 20 ng/mL before infusion, with many clinicians targeting 30 to 50 ng/mL. Supplementing patients with at least 1,200 mg of calcium and 800 to 1,000 IU of vitamin D daily during treatment is standard practice per Endocrine Society clinical guidelines [5]. Serum calcium should be checked 7 to 10 days after infusion in patients at elevated risk.

Renal Adverse Events

Zoledronic acid is filtered by the kidney via glomerular filtration and active tubular secretion. Rapid infusion or a high single dose concentrates the drug in proximal tubular cells and can cause focal segmental glomerulosclerosis or tubular necrosis. The FDA label mandates that the 5 mg dose be infused over no less than 15 minutes [2]. Reclast is contraindicated when creatinine clearance falls below 35 mL/min. Post-market FDA safety communications have highlighted acute kidney injury events in patients who received the infusion too quickly or who were dehydrated [6].

Monitoring Recommendations

Serum creatinine should be assessed before each annual infusion. Patients with borderline renal function (creatinine clearance 35 to 60 mL/min) benefit from aggressive pre- and post-infusion hydration and a longer infusion duration of 30 minutes rather than 15.

Osteonecrosis of the Jaw (ONJ)

ONJ is defined as exposed, necrotic bone in the jaw region persisting for more than eight weeks in the absence of radiation therapy to the jaw. In osteoporosis dosing regimens, ONJ is rare. A 2014 systematic review published in the Journal of Clinical Oncology estimated the incidence at 1 per 10,000 to 1 per 100,000 patient-years for oral bisphosphonates and oncology IV regimens respectively [7]. For the annual 5 mg zoledronic acid dose, population-level incidence is at the lower end of that range.

Risk Factors

Dental extraction, dental implant placement, denture trauma, poor oral hygiene, smoking, corticosteroid use, and chemotherapy all raise ONJ risk. The 2022 ASBMR task force position paper recommends completing necessary invasive dental procedures before starting zoledronic acid and maintaining routine dental hygiene throughout treatment [8].

Clinical Guidance

Patients should notify their dentist about zoledronic acid use before any dental procedure. A drug holiday before elective invasive dental work is sometimes considered, but evidence supporting a specific holiday duration is weak. Most expert guidelines do not recommend routine pre-procedural drug holidays for patients on osteoporosis dosing given the low ONJ incidence and the fracture risk of stopping therapy.

Atypical Femur Fractures (AFF)

Atypical femur fractures are low-energy, transverse or short oblique fractures of the subtrochanteric or diaphyseal femur. They are associated with prolonged bisphosphonate use, thought to result from over-suppression of bone remodeling that allows accumulation of microdamage. An FDA safety communication issued in 2010 and updated in 2011 required bisphosphonate labels to include AFF warnings [6].

Incidence Over Time

The absolute risk is low but duration-dependent. An analysis published in the New England Journal of Medicine using Swedish registry data (N=12,777 AFF cases) found that AFF risk increased with longer bisphosphonate use, with a rate ratio of 8.0 (95% CI 5.2 to 12.4) among users of more than five years compared to non-users [9]. At three years of use, the estimated absolute risk is approximately 3.4 per 100,000 person-years, rising to about 113 per 100,000 person-years at 10 years of use.

Prodromal Symptoms

Up to 70% of patients with AFF report prodromal thigh or groin pain weeks to months before fracture. Clinicians should obtain a femoral X-ray or MRI when bisphosphonate-treated patients report new thigh pain, looking for cortical thickening or stress reaction on the lateral cortex.

Ocular Adverse Events

Uveitis, scleritis, and conjunctivitis have been reported with IV bisphosphonates, including zoledronic acid. A 2012 case series in the Canadian Journal of Ophthalmology described 10 cases of ocular inflammation temporally associated with zoledronic acid infusion, most resolving with topical steroids within two weeks [10]. Patients with new eye pain, redness, or visual changes after infusion should be evaluated by an ophthalmologist promptly.

Atrial Fibrillation

The HORIZON-PFT trial found a numerical imbalance in serious atrial fibrillation (AF) events: 1.3% in the zoledronic acid group versus 0.5% in the placebo group (P<0.001 for the difference at three years) [3]. The FDA reviewed this signal in 2008 and concluded that available data were insufficient to establish a causal relationship [6]. Subsequent meta-analyses have produced conflicting results, and current prescribing guidance does not list pre-existing AF as a contraindication.

Zoledronic Acid Withdrawal and Discontinuation Syndrome

This is an area of active clinical concern. Unlike oral bisphosphonates, which have a shorter skeletal half-life, zoledronic acid is retained in bone for years. Some patients and clinicians interpret this as meaning the drug can be stopped freely without bone loss. The evidence does not fully support that interpretation.

What Happens to Bone Turnover After Stopping

After the last zoledronic acid infusion, bone turnover markers (BTMs) such as serum C-terminal telopeptide (CTX) and procollagen type 1 N-terminal propeptide (P1NP) rebound upward, sometimes exceeding pre-treatment levels. The HORIZON extension study showed that CTX rose from suppressed levels back toward baseline by 12 months after stopping the drug in patients who discontinued after three annual doses [11]. In patients who stopped after six doses, BTM rebound was slower, consistent with greater skeletal drug loading.

Bone Mineral Density Loss After Discontinuation

Bone mineral density (BMD) at the spine and hip begins to fall after stopping zoledronic acid, but the rate and magnitude depend heavily on how long the patient was treated. In the HORIZON extension (N=1,233 extended to 6 years), patients who stopped zoledronic acid after three years lost approximately 1 to 2% of hip BMD per year over the following three years [11]. Patients who continued for six years maintained BMD gains and had lower BTM levels when treatment was stopped.

Rebound Vertebral Fractures

The most clinically significant concern after stopping zoledronic acid is the risk of rebound vertebral fractures. A 2019 analysis in the Journal of Bone and Mineral Research reviewed post-trial fracture data and found that vertebral fracture incidence rose significantly within 12 to 24 months of stopping IV bisphosphonate therapy in high-risk patients [12]. In some cohorts, the rate of multiple vertebral fractures reached 9.8% within 24 months of discontinuation, with clustering of events suggesting a rebound hyperresorptive state.

This pattern is not identical to the well-described denosumab (Prolia) rebound fracture cascade, where BTMs spike sharply and multiple vertebral fractures can occur within months of a single missed dose. Zoledronic acid's skeletal retention provides a slower, more attenuated rebound. However, high-risk patients, particularly those with prior vertebral fractures, very low T-scores (below minus 2.5), or a history of multiple fragility fractures, remain vulnerable after stopping.

The Drug Holiday Decision: A Structured Approach

Bisphosphonate drug holidays are supported by the American College of Physicians (ACP), ASBMR, and Endocrine Society for select patients after adequate treatment duration. The 2022 ASBMR task force white paper provides the most current guidance [8]:

• Patients at low-to-moderate fracture risk after 3 years of IV zoledronic acid therapy may consider a drug holiday of 3 years.
• Patients at high fracture risk (prior vertebral fracture, femoral neck T-score below minus 2.5, or FRAX 10-year major osteoporotic fracture probability above 20%) should continue for 6 years before reassessment.
• After a holiday, BMD and BTMs should be reassessed at 2-year intervals. Restart therapy if hip BMD declines by 5% or more, if BTMs rise significantly above the premenopausal reference range, or if a new fragility fracture occurs.

The task force stated: "The benefits of a drug holiday in low-risk patients include reducing the cumulative incidence of rare but serious AFF events, while the principal risk is fracture recurrence in those with residual skeletal fragility" [8].

Rare but Serious Adverse Events

Severe Bone, Joint, and Muscle Pain

FDA updated bisphosphonate labels in 2008 to include a warning that severe and sometimes incapacitating musculoskeletal pain may occur days, months, or years after starting therapy [6]. Pain typically resolves after stopping the drug but may not fully resolve in all cases. This is distinct from the acute post-infusion myalgia, which resolves within days.

Hypersensitivity and Anaphylaxis

Serious hypersensitivity reactions including anaphylaxis have been reported post-market. The reaction rate is low, estimated at fewer than 1 in 10,000 infusions based on FAERS data, but patients receiving their first infusion in a clinic should be monitored for at least 30 minutes after completion.

Esophageal Cancer (Oral Bisphosphonates Only)

FDA issued a safety communication in 2011 regarding esophageal cancer with oral bisphosphonates after reports from FAERS and a NEJM correspondence. This warning does not apply to IV zoledronic acid, which bypasses the esophagus entirely [6].

Special Populations

Pregnancy and Lactation

Zoledronic acid is FDA Pregnancy Category D (old classification) and is contraindicated in pregnancy. Animal data show fetal harm. The drug should be stopped before conception in women of childbearing potential and should not be used during breastfeeding [2].

Patients With Prior Denosumab Use

Transitioning from denosumab to zoledronic acid requires careful timing. If the first zoledronic acid dose is given at the 6-month mark after the last denosumab injection, it substantially reduces the rebound BTM spike and risk of rebound vertebral fractures. A 2021 study in Osteoporosis International (N=72) found that timely zoledronic acid infusion 6 months after denosumab discontinuation prevented the BMD loss and BTM rebound seen in patients who received no bridging therapy [13]. Administering zoledronic acid later than 7 months after the last denosumab dose may be insufficient to prevent the full rebound effect.

Glucocorticoid-Induced Osteoporosis

Zoledronic acid is FDA-approved for treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to receive at least 7.5 mg/day prednisone equivalent for 12 or more months. In this population, the HORIZON Reclast Glucocorticoid-Induced Osteoporosis Study showed significantly greater lumbar spine BMD gains at 12 months compared to risedronate (P<0.05) [14].

Monitoring and Safety Checklist Before and After Infusion

Clinicians prescribing zoledronic acid should confirm the following before each infusion:

1. Creatinine clearance is at or above 35 mL/min.
2. Serum calcium is within the normal range.
3. 25-hydroxyvitamin D level is above 20 ng/mL.
4. The patient has had a dental evaluation in the past 12 months.
5. The patient is not pregnant or planning pregnancy within 12 months.
6. Informed consent includes discussion of ONJ, AFF, renal risk, and the post-infusion reaction.

After infusion, patients should be instructed to report persistent jaw pain, new thigh or groin pain lasting more than two weeks, severe eye pain or redness, or signs of hypocalcemia such as perioral tingling, muscle cramps, or carpopedal spasm.